William Blair & Company
MYGN icon

William Blair & Company’s Myriad Genetics MYGN Stock Holding History

William Blair & Company’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,866
Closed -$190K – 1827
2023
Q3 		$190K Hold
11,866
– – ﹤0.01% 1400
2023
Q2 		$275K Hold
11,866
– – ﹤0.01% 1281
2023
Q1 		$276K Hold
11,866
– – ﹤0.01% 1271
2022
Q4 		$172K Sell
11,866
-3
-0% -$56 ﹤0.01% 1400
2022
Q3 		$226K Sell
11,869
-214
-2% -$4.91K ﹤0.01% 1342
2022
Q2 		$220K Buy
12,083
+214
+2% +$4.44K ﹤0.01% 1380
2022
Q1 		$299K Sell
11,869
-250
-2% -$6.4K ﹤0.01% 1367
2021
Q4 		$334K Sell
12,119
-50,000
-80% -$1.45M ﹤0.01% 1379
2021
Q3 		$2.01M Buy
62,119
+50,000
+413% +$1.66M 0.01% 704
2021
Q2 		$371K Hold
12,119
– – ﹤0.01% 1269
2021
Q1 		$369K Hold
12,119
– – ﹤0.01% 1255
2020
Q4 		$240K Sell
12,119
-3,277
-21% -$52.9K ﹤0.01% 1356
2020
Q3 		$201K Sell
15,396
-63
-0.4% -$797 ﹤0.01% 1301
2020
Q2 		$175K Sell
15,459
-1,618
-9% -$23K ﹤0.01% 1275
2020
Q1 		$244K Buy
17,077
+1,886
+12% +$39.8K ﹤0.01% 1087
2019
Q4 		$414K Hold
15,191
– – ﹤0.01% 1059
2019
Q3 		$435K Hold
15,191
– – ﹤0.01% 992
2019
Q2 		$458K Sell
15,191
-269
-2% -$7.6K ﹤0.01% 1010
2019
Q1 		$513K Sell
15,460
-528
-3% -$16.1K ﹤0.01% 958
2018
Q4 		$482K Sell
15,988
-1,100
-6% -$39.6K ﹤0.01% 920
2018
Q3 		$786K Buy
17,088
+1,900
+13% +$84.5K ﹤0.01% 814
2018
Q2 		$568K Hold
15,188
– – ﹤0.01% 910
2018
Q1 		$449K Hold
15,188
– – ﹤0.01% 955
2017
Q4 		$522K Sell
15,188
-35,560
-70% -$1.2M ﹤0.01% 956
2017
Q3 		$1.84M Buy
50,748
+10,188
+25% +$291K 0.01% 574
2017
Q2 		$1.05M Buy
+40,560
New +$861K 0.01% 737
2014
Q3 		– Sell
-5,275
Closed -$204K – 2147
2014
Q2 		$204K Buy
+5,275
New +$196K ﹤0.01% 1945
2013
Q3 		– Sell
-538,847
Closed -$14.5M – 2063
2013
Q2 		$14.5M Buy
+538,847
New +$15.6M 0.03% 576

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

William Blair & Company's MYGN Position: Q4 2023 in Review

William Blair & Company sold out of Myriad Genetics (MYGN) in Q4 2023, closing a stake of 11,866 shares — an estimated $190K sold.

William Blair & Company first reported a position in MYGN in Q2 2013 and held it in 28 quarters. The position peaked at $14.5M in Q2 2013. 194 funds tracked by Wall St. Rank hold MYGN as of Q4 2023.

  • William Blair & Company reported no remaining Myriad Genetics position as of Q4 2023 after selling out during the quarter.
  • William Blair & Company sold 11,866 Myriad Genetics shares in Q4 2023, an estimated $190K.
  • William Blair & Company first reported a position in Myriad Genetics in Q2 2013 and held it in 28 quarters.
  • William Blair & Company's Myriad Genetics position peaked at $14.5M in Q2 2013.
  • 194 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2023.

Based on William Blair & Company's 13F filing for Q4 2023, filed 12 Feb 2024.